You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
雲頂新耀-B(01952.HK):與KEZAR訂立合作及授權許可協議

格隆匯9月21日丨雲頂新耀-B(01952.HK)發佈公吿,2023年9月21日,公司與Kezar Life Sciences, Inc.(“Kezar”,一家於納斯達克上市的公司,股份代號:KZR)訂立合作及授權許可協議,據此,Kezar授予公司獨家授權許可,在大中華區、韓國及若干東南亞國家開發、生產及商業化Kezar的主要候選藥物zetomipzomib,其為一種用於治療包括狼瘡性腎炎在內的一系列自身免疫性疾病的新同類首創選擇性免疫蛋白酶體抑制劑。

根據授權許可協議,授權許可費包括:(i)預付款700萬美元(相當於約人民幣5100萬元);及(ii)潛在臨牀及商業里程碑款項最多1.255億美元(相當於約人民幣9.147億元)。

公司將與Kezar共同推進全球2b期PALIZADE臨牀研究,以評估兩種劑量水平的zetomipzomib對活動期狼瘡性腎炎患者的療效及安全性。PALIZADE全球研究已於2023年年中啟動,目標入組人數為279名患者。前期臨牀試驗所得的數據表明zetomipzomib在治療狼瘡性腎炎上表現出良好的安全性及耐受性,狼瘡性腎炎患者在使用zetomipzomib治療6個月後表現出具有臨牀意義的總體腎臟治療效果。除狼瘡性腎炎外,公司與Kezar有機會在未來就其他自身免疫疾病如系統性紅斑狼瘡的臨牀試驗及適應症方面進行合作,從而繼續開發zetomipzomib。

董事認為,公司與Kezar之間的策略合作將豐富公司現有的腎臟產品管線,並有助鞏固公司在腎病及自身免疫性疾病(公司在亞洲的重點治療領域)的領先地位。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account